Disc Medicine, Inc. (IRON) Research

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Market snapshot

Symbol
IRON
Price
$70.79
Day change
+0.83%
Market cap
$2.7B
P/E ratio
-11.28x
52-week range
40-99.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$101.6

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Adaptive Biotechnologies Corporation (ADPT)
  • Apogee Therapeutics, Inc. (APGE)
  • Celcuity Inc. (CELC)
  • CG Oncology, Inc. Common stock (CGON)
  • Legend Biotech Corporation (LEGN)
  • Scholar Rock Holding Corporation (SRRK)
  • Tarsus Pharmaceuticals, Inc. (TARS)

Recent insider activity

  • Yu Jonathan Yen-Wen — M-Exempt (13351 shares) on 2026-06-16
  • Yu Jonathan Yen-Wen — S-Sale (11651 shares) on 2026-06-16
  • Yu Jonathan Yen-Wen — M-Exempt (5261 shares) on 2026-06-16
  • Yu Jonathan Yen-Wen — S-Sale (6961 shares) on 2026-06-16
  • Yu Jonathan Yen-Wen — M-Exempt (13351 shares) on 2026-06-16

Open Disc Medicine, Inc. (IRON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.